MedCap's adjusted EBITA increased 28% in Q2 2026
Net sales rose 16% to SEK 606.3 million, with organic growth of 7%. The EBITA margin improved to 21.4%.
See the latest news and media coverage for MedCap. We track all announcements, press releases, and industry mentions in real time, all in one place.
Acquirer and developer of life science companies
medcap.seLast updated
In short: MedCap reported strong growth in Q2 2026, with revenue rising 16% to 606.3 MSEK and adjusted EBITA increasing 28% to 125 MSEK.
Net sales rose 16% to SEK 606.3 million, with organic growth of 7%. The EBITA margin improved to 21.4%.
Biopsafe provides innovative containers for biopsies with a turnover of approximately 50 MDKK and good profitability.
The board uses authorization to repurchase shares up to 25 MSEK on Nasdaq Stockholm to ensure LTIP 2026/2029 and adjust the capital structure.
The meeting elected a new board with Karl Tobieson as chairman, approved LTIP 2026 with 200,000 options and authorized share buybacks and issuances.
Jul. 21 MedCap AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI Jul. 21 Medcap increased revenue and...
Linc-owned Medcap, which invests in Life science, had an adjusted EBITA result of 125 million kronor (97.5) in the second quarter of 2026.
MedCap AB ( (SE:MCAP)) has provided an announcement. MedCap AB has expanded its MedTech business area by acquiring Danish company Biopsafe ApS, which supplies an...
Medcap, which is an investment company within pharmaceuticals and medical technology, reports a net profit of 55.7 million kronor for the first quarter...
Track MedCap and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to MedCap and other trending companies.